Regeneron received emergency approval for its coronavirus cocktail therapy from the U.S. Food & Drug Administration.
The company said its REGN-COV2 treatment, a combination of two monoclonal antibodies designed to prevent the infectivity of SARS-CoV-2, the virus that causes COVID-19, was granted Emergency Use Authorization (EUA) from the FDA Sunday. Regeneron said the approval is for individuals who are at high risk for progressing to severe COVID-19 or possible hospitalization.
"This FDA Emergency Use Authorization is an important step in the fight against COVID-19, as high-risk patients in the United States will have access to a promising therapy early in the course of their infection," said CEO Leonard Schleifer. "The science and technology investments Regeneron has made over three decades positioned us to move rapidly to invent, study and maximize production of REGEN-COV2."